{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:08:41Z","timestamp":1791238121537,"version":"4.1.0"},"reference-count":28,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1586\/14737140.2.2.143","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T07:51:56Z","timestamp":1105602716000},"page":"143-150","source":"Crossref","is-referenced-by-count":105,"title":["Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer"],"prefix":"10.1586","volume":"2","author":[{"given":"T","family":"Tejada-Berges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CO","family":"Granai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gordinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0168-3659(97)00261-7","volume":"53","author":"Gabizon A","year":"1998","journal-title":"\/ Contra Rel"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04152.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/380561a0"},{"key":"CIT0005","first-page":"51","volume":"13","author":"Northfelt DW Stealth liposomal doxorubicin","year":"1994","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/JCO.1997.15.2.653","volume":"15","author":"Northfelt DW","year":"1997","journal-title":"J Gun. Oncol"},{"key":"CIT0010","first-page":"S47","volume":"23","author":"Smith PJ","year":"1994","journal-title":"Br. J Cancer"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","volume":"16","author":"Bookman MA","year":"1998","journal-title":"j Clin. Oncol"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4787"},{"key":"CIT0016","first-page":"1062","volume":"18","author":"McGuire WP","year":"2000","journal-title":"A Gynecologic Oncology Group Study.\/ Clin. Oncol"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"Rose PG","year":"1998","journal-title":"J Clin. Oncol"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0284"},{"key":"CIT0019","first-page":"710","volume":"91","author":"Von hoff DD, Layard MW,","year":"1979","journal-title":"Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-99-6-745","volume":"99","author":"Torti FM","year":"1999","journal-title":"Ann. Intern. Med"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1995.13.3.726","volume":"13","author":"AHem RP","year":"1995","journal-title":"j Clin. Oncol"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A"},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","volume":"15","author":"MI iggia FM, Hainsworth JD, Jeffers S et al.","year":"1997","journal-title":"\/ Clin. Oncol"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5819"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"Gordon AN","year":"2000","journal-title":"\/ Clin. Oncol"},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","volume":"81","author":"Campos SM","year":"2001","journal-title":"Gynecol. Oncol"},{"key":"CIT0039","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/1097-0142(20011101)92:9<2327::AID-CNCR1579>3.0.CO;2-6","volume":"92","author":"Verschraegen CF","year":"2001","journal-title":"Cancer"},{"key":"CIT0042","first-page":"1936","volume":"92","author":"Fabel K","year":"2001","journal-title":"Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jnci\/88.11.734","volume":"88","author":"Kaufman SH","year":"1996","journal-title":"J. Natl Cancer Inst"},{"key":"CIT0047","first-page":"3117","volume":"19","author":"Sparano JA","year":"2001","journal-title":"Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J. Clin. Onca"},{"key":"CIT0048","first-page":"1113","volume":"10","author":"Burstein H","year":"1999","journal-title":"Phase I study of Caelyx\/Doxil and vinorelbine in metastatic breast cancer. Ann. Oncol"},{"key":"CIT0052","unstructured":"Moore MR, Srinivasiah J, Feinberg BA et al. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HC1 liposome injection (Caelyx\/Doxil) plus paclitaxel (DT) in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. Los Angeles, CA, USA (1998)."},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"Gordon AN","year":"2001","journal-title":"j Clin. Oncol"},{"key":"CIT0058","unstructured":"Harris L, Winer E, Batist G et al. Phase III study of TLC D-99 (liposome-encapsulated doxorubicin) vs. free doxorubicin in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. Los Angeles, CA, USA (1998)."},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(20010501)91:9<1826::AID-CNCR1203>3.0.CO;2-J","volume":"91","author":"Hong RL","year":"2001","journal-title":"Cancer"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737140.2.2.143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T20:34:03Z","timestamp":1547411643000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737140.2.2.143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1586\/14737140.2.2.143"],"URL":"https:\/\/doi.org\/10.1586\/14737140.2.2.143","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}